United States FDA accepts filing with priority review for ozanimod for treating ulcerative colitis
The supplemental New Drug Application to the FDA is supported by positive results from the Phase 3 True North study. This evaluated ozanimod as an induction and maintenance therapy in adults with moderately to severely active UC.
Source:
Biospace Inc.
SPS commentary:
Ozanimod is an oral selective sphingosine 1-phosphate 1 receptor (S1P1R) modulator currently being investigated for ulcerative colitis and Crohn’s disease.